Clinical Edge Journal Scan

Aortic Stiffness Elevated in Patients With PsA


 

Key clinical point: Aortic stiffness was significantly higher in individuals with vs without psoriatic arthritis (PsA), and a longer disease duration was a predictor of increased aortic stiffness in the PsA population.

Major finding: Aortic stiffness, measured by carotid femoral pulse wave velocity, was significantly higher in patients with PsA than in healthy individuals without systemic inflammatory disease (7.80 vs 6.76 m/s; regression coefficient [ β] 0.457; Padj = .034). Aortic stiffness was positively associated with disease duration ( β 0.028; Padj = .020), red cell distribution width (Pearson correlation coefficient 0.190; P = .020), and systolic blood pressure (Spearman correlation coefficient [ ρ] 0.351; P < .001), and inversely associated with glomerular filtration rate ( ρ − 0.264; P = .001).

Study details: This prospective PSOriatic Arthritis CARDiovascular Disease cohort included 150 patients with PsA and 88 healthy individuals without systemic inflammatory disease.

Disclosures: This study did not receive any specific funding. One author declared being an editorial board member of Rheumatology and Therapy. Other authors declared no conflicts of interest.

Source: Triantafyllias K, Liverakos S, Muthuraman M, et al. Cardiovascular risk evaluation in psoriatic arthritis by aortic stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the prospective PSOCARD cohort study. Rheumatol Ther. 2024 (May 31). doi: 10.1007/s40744-024-00676-z Source

Recommended Reading

Study Finds Mace Risk Remains High in Patients with Psoriasis, Dyslipidemia
MDedge Rheumatology
Over-the-Counter Arthritis Supplements Pose Adrenal Danger
MDedge Rheumatology
Clear Coverage Preference for Humira Over Biosimilars Seen in Most Medicare Part D Plans
MDedge Rheumatology
EULAR 2024 Preview: Therapeutics in Development Take Center Stage
MDedge Rheumatology
Low Stress Resilience in Adolescence Raises Risk for Psoriatic Arthritis
MDedge Rheumatology
Real-World Prevalence and Clinical Characteristics of Difficult-To-Treat PsA
MDedge Rheumatology
Risankizumab Effective in Resolving Enthesitis and Dactylitis in PsA
MDedge Rheumatology
Bimekizumab Eases Disease Impact in bDMARD-naive, TNFi-IR Patients with PsA
MDedge Rheumatology
Ixekizumab Effective in PsA Irrespective of Extent of Initial Skin Involvement
MDedge Rheumatology
Treatment With Biologics Reduces Risk for PsA in Psoriasis
MDedge Rheumatology